Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN)

被引：0
|
作者：
Bruemmendorf, T. [1 ]
Guigay, J. [2 ]
Mesia, R. [3 ]
Trigo, J. [4 ]
Keilholz, U. [5 ]
Dittrich, C. [6 ,7 ]
Kerber, A. [8 ]
Picard, M. [8 ]
Vermorken, J. [9 ]
机构：
[1] UCCH, Univ Med Ctr Eppendorf, Dept Hematol & Oncol, Hamburg, Germany
[2] Inst Gustave Roussy, Villejuif, France
[3] Inst Catala Oncol Hosp, Barcelona, Spain
[4] Hosp Univ Virgen Victoria, Malaga, Spain
[5] Hematol & Med Oncol CBF, Charite, Berlin, Germany
[6] ACR ITR VIEnna, Vienna, Austria
[7] KFJ Spital, LBI ACR VIEnna, Vienna, Austria
[8] Merck KGaA, Global Clin Dev Unit, Darmstadt, Germany
[9] Univ Hosp Antwerpen, Edegem, Belgium
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：475 / 476
页数：2
相关论文
共 50 条
  • [21] A phase I, open-label study of lapatinib plus chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN).
    Harrington, K. J.
    Bourhis, J.
    Nutting, C. M.
    Rosine, D.
    Theodosiou, A. M.
    Gardiner, S.
    Berger, M. S.
    Beelen, A. P.
    Stead, A. G.
    El-Hariry, I. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 293S - 293S
  • [22] Phase I-II study with docetaxel (D), cisplatin (C) and 5-Fluorouracil (5-FU) in patients with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)
    Schrijvers, D
    Van Herpen, C
    Kerger, J
    Joosens, E
    Brandely, M
    Vermorken, JB
    ANNALS OF ONCOLOGY, 1998, 9 : 75 - 75
  • [23] A phase I study of avelumab, palbociclib, and cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma
    Dennis, Michael J.
    Sacco, Assuntina G.
    Qi, Yuchen
    Bykowski, Julie
    Pittman, Emily
    Chen, Ruifeng
    Messer, Karen
    Cohen, Ezra E. W.
    Gold, Kathryn A.
    ORAL ONCOLOGY, 2022, 135
  • [24] Phase I study of ribociclib plus cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck
    Seront, E.
    Schmitz, S.
    Rottey, S.
    Henry, S.
    Lonchay, C.
    van Caloen, G.
    Gilain, A.
    Machiels, J-P.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Fayette, J.
    Lefebvre, G.
    Posner, M. R.
    Bauman, J.
    Salas, S.
    Even, C.
    Saada-Bouzid, E.
    Seiwert, T.
    Colevas, D.
    Calmels, F.
    Zerbib, R.
    Chammard, A. Boyer
    Cohen, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 374 - 374
  • [26] PHASE IB TRIAL OF IMO-2055 IN COMBINATION WITH 5-FU, CISPLATIN AND CETUXIMAB IN 1ST-LINE PTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN)
    Machiels, J. P.
    Kaminsky, M. C.
    Keller, U.
    Bruemmendorf, T. H.
    Goddemeier, T.
    Forssman, U.
    Delord, J. P.
    ANNALS OF ONCOLOGY, 2012, 23 : 342 - 342
  • [27] PHASE-I-II TRIAL WITH CISPLATIN AND 5-FU IN RECURRENT HEAD AND NECK-CANCER - AN EFFECTIVE OUTPATIENT SCHEDULE
    MERLANO, M
    TATAREK, R
    GRIMALDI, A
    MARGARINO, G
    ROSSO, R
    CANCER TREATMENT REPORTS, 1985, 69 (09): : 961 - 964
  • [28] Cetuximab, Fluorouracil (5-FU), Ciplatin and Docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCID).
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher-Williams, J.
    Gruenwald, V
    Rethwisch, V.
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2013, 36 : 94 - 94
  • [29] Phase I-II study with docetaxel (D), cisplatin (C) and 5-fluorouracil (5-FU) in patients (pts) with locally advanced inoperable squamous cell carcinoma of the head and neck (SCCHN)
    Schrijvers, D
    Van Herpen, C
    Kerger, J
    Joosens, E
    Le Bouder, C
    Castelijns, J
    Awada, A
    Vermorken, JB
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S164 - S164
  • [30] PHASE-I STUDY OF PACLITAXEL, CISPLATIN, AND IFOSFAMIDE IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS-CELL CANCER OF THE HEAD AND NECK
    BENNER, SE
    LIPPMAN, SM
    HUBER, MH
    HONG, WK
    SEMINARS IN ONCOLOGY, 1995, 22 (05) : 22 - 25
12345